Literature DB >> 19853839

The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine.

Janet Hoenicka1, Adolfo Quiñones-Lombraña, Laura España-Serrano, Ximena Alvira-Botero, Leonor Kremer, Rocío Pérez-González, Roberto Rodríguez-Jiménez, Miguel Angel Jiménez-Arriero, Guillermo Ponce, Tomás Palomo.   

Abstract

BACKGROUND: TaqIA, the most widely analyzed genetic polymorphism in addictions, has traditionally been considered a gene marker for association with D2 dopamine receptor gene (DRD2). TaqIA is located in the coding region of the ANKK1 gene that overlaps DRD2 and encodes a predicted kinase ANKK1. The ANKK1 protein nonetheless had yet to be identified. This study examined the ANKK1 expression pattern as a first step to uncover the biological bases of TaqIA-associated phenotypes.
METHODS: Northern blot and quantitative reverse-transcriptase polymerase chain reaction analyses were performed to analyze the ANKK1 mRNA. To study ANKK1 protein expression, we developed two polyclonal antibodies to a synthetic peptides contained in the putative Ser/Thr kinase domain.
RESULTS: We demonstrate that ANKK1 mRNA and protein were expressed in the adult central nervous system (CNS) in human and rodents, exclusively in astrocytes. Ankk1 mRNA level in mouse astrocyte cultures was upregulated by apomorphine, suggesting a potential relationship with the dopaminergic system. Developmental studies in mice showed that ANKK1 protein was ubiquitously located in radial glia in the CNS, with an mRNA expression pick around embryonic Day 15. This time expression pattern coincided with that of the Drd2 mRNA. On induction of differentiation by retinoic acid, a sequential expression was found in human neuroblastoma, where ANKK1 was expressed first, followed by that of DRD2. An opposite time expression pattern was found in rat glioma.
CONCLUSIONS: Spatial and temporal regulation of the expression of ANKK1 suggest an involvement of astroglial cells in TaqIA-related neuropsychiatric phenotypes both during development and adult life.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19853839     DOI: 10.1016/j.biopsych.2009.08.012

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  33 in total

1.  PharmGKB summary: dopamine receptor D2.

Authors:  Huaiyu Mi; Paul D Thomas; Huijun Z Ring; Ruhong Jiang; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-06       Impact factor: 2.089

2.  Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans.

Authors:  Orna Levran; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Ann Hum Genet       Date:  2015-02-27       Impact factor: 1.670

3.  Dietary triglycerides as signaling molecules that influence reward and motivation.

Authors:  Chloé Berland; Céline Cansell; Thomas S Hnasko; Christophe Magnan; Serge Luquet
Journal:  Curr Opin Behav Sci       Date:  2016-03-18

Review 4.  Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction.

Authors:  Laura L Giacometti; Jacqueline M Barker
Journal:  Brain Res       Date:  2019-08-14       Impact factor: 3.252

5.  Association of a common genetic variant within ANKK1 with six-month cognitive performance after traumatic brain injury.

Authors:  John K Yue; Angela M Pronger; Adam R Ferguson; Nancy R Temkin; Sourabh Sharma; Jonathan Rosand; Marco D Sorani; Thomas W McAllister; Jason Barber; Ethan A Winkler; Esteban G Burchard; Donglei Hu; Hester F Lingsma; Shelly R Cooper; Ava M Puccio; David O Okonkwo; Ramon Diaz-Arrastia; Geoffrey T Manley
Journal:  Neurogenetics       Date:  2015-01-30       Impact factor: 2.660

6.  Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Xu Shu; Jurg Ott; Pei-Hong Shen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

7.  Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status.

Authors:  Sarah A Eisenstein; Ryan Bogdan; Latisha Love-Gregory; Nadia S Corral-Frías; Jonathan M Koller; Kevin J Black; Stephen M Moerlein; Joel S Perlmutter; Deanna M Barch; Tamara Hershey
Journal:  Synapse       Date:  2016-06-17       Impact factor: 2.562

Review 8.  The genetic epidemiology of substance use disorder: A review.

Authors:  Elizabeth C Prom-Wormley; Jane Ebejer; Danielle M Dick; M Scott Bowers
Journal:  Drug Alcohol Depend       Date:  2017-08-01       Impact factor: 4.492

Review 9.  Epigenetics and biomarkers in the staging of neuropsychiatric disorders.

Authors:  Trevor Archer; Richard J Beninger; Tomas Palomo; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

10.  The TaqIA RFLP is associated with attenuated intervention-induced body weight loss and increased carbohydrate intake in post-menopausal obese women.

Authors:  Jameason D Cameron; Marie-Ève Riou; Frédérique Tesson; Gary S Goldfield; Rémi Rabasa-Lhoret; Martin Brochu; Éric Doucet
Journal:  Appetite       Date:  2012-09-29       Impact factor: 3.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.